Biomea Fusion (BMEA) Set to Announce Quarterly Earnings

Biomea Fusion (NASDAQ:BMEA) is preparing to release its quarterly earnings results on Monday, March 24th, before the market opens. Analysts predict that the company will report earnings of ($1.00) per share for this period.

Market Performance

On Friday, Biomea Fusion stock opened at $2.87. The company has a market capitalization of $104.01 million and a price-to-earnings ratio of -0.72, indicating its negative earnings per share during the evaluated period. The stock has shown a beta of -0.26, suggesting lower volatility compared to the market. Over the past year, Biomea Fusion's stock has seen a low of $2.35 and a high of $16.97. A fifty-day simple moving average stands at $3.47, while the two-hundred day simple moving average is at $6.18.

Analyst Ratings and Predictions

Several analysts have provided their insights regarding Biomea Fusion's stock performance. HC Wainwright recently reaffirmed a "buy" rating and set a price target of $40.00 on the shares as of January 14th. Additionally, D. Boral Capital has also expressed a positive outlook by maintaining a "buy" rating with a price objective of $16.00. The consensus from a total of thirteen research analysts includes nine who have issued buy ratings, two who have rated it as a strong buy, and two maintaining a hold rating. MarketBeat indicates that Biomea Fusion currently carries an average price target of $29.18 based on the analysts' evaluations.

About Biomea Fusion

Biomea Fusion, Inc. is a clinical-stage biopharmaceutical company that focuses on discovering and developing covalent small molecule drugs aimed at treating genetically defined cancers and metabolic diseases. Their lead product candidate, BMF-219, is designed as a covalent inhibitor of menin, targeted at patients with both liquid and solid tumors and those with type 2 diabetes.

earnings, stocks, biotech